Daniel Trey Lee, Clinical Fellow
Daniel “Trey” Lee received his Doctor of Medicine degree from the University of Texas Health Science Center in Houston and trained in pediatrics at the University of Texas Health Science Center and Hermann Children’s Hospital. He then completed subspecialty training in Pediatric Hematology/Oncology via the Joint NCI/Johns Hopkins Fellowship Program. Prior to his arrival at NIH, Dr. Lee conducted research at M.D. Anderson Cancer Center under the mentorship of Dr. Seth Corey, where he identified a role for microRNA mediated modulation of SHIP-1 in high risk myelodysplastic syndrome (Lee et al, Oncogene, 2012). His work in the Immunology Section has focused on clinical development of CD19-targeted chimeric antigen receptor therapy for childhood acute lymphoblastic leukemia. He serves as Lead Associate Investigator on a clinical trial initiated in 2012 to test this therapy in children and he is conducting xenograft studies that are elucidating an essential role for CD4+ chimeric antigen receptor T cells in eradicating acute lymphoblastic leukemia in vivo. He is married, has one cat, Chase, and is a devout fan of University of Texas football and the Spurs.